Table 4.
Odds ratio (OR) and 95% confidence intervals (CI) of UGT1A7 genotype for hepatocellular carcinoma (HCC)
| Position | Genotype | OR1 (95% CI) | P1 | OR2 (95% CI) | P 2 |
|---|---|---|---|---|---|
| –341 | CC | 1.00 (reference) | 1.00 (reference) | ||
| CT | 1.41 (0.97–2.04) | 0.07 | 1.43 (0.95–2.16) | 0.09 | |
| TT | 2.14 (0.35–12.9) | 0.41 | 0.6 (0.14–2.55) | 0.49 | |
| –57 | TT | 1.00 (reference) | 1.00 (reference) | ||
| TG | 0.91 (0.64–1.29) | 0.60 | 1.30 (0.88–1.90) | 0.19 | |
| GG | 0.76 (0.38–1.51) | 0.43 | 1.39 (0.62–3.15) | 0.42 | |
| 33 | CC | 1.00 (reference) | 1.00 (reference) | ||
| CA | 1.06 (0.75–1.51) | 0.73 | 1.30 (0.88–1.90) | 0.19 | |
| AA | 0.82 (0.39–1.75) | 0.62 | 1.22 (0.51–2.91) | 0.66 | |
| 387 | TT | 1.00 (reference) | 1.00 (reference) | ||
| TG | 1.24 (0.84–1.81) | 0.28 | 1.64 (1.09–2.47) | 0.02 | |
| GG | 1.55 (0.94–2.55) | 0.08 | 1.94 (1.13–3.33) | 0.02 | |
| 391 | CC | 1.00 (reference) | 1.00 (reference) | ||
| AC | 1.24 (0.84–1.81) | 0.28 | 1.64 (1.09–2.47) | 0.02 | |
| AA | 1.55 (0.94–2.55) | 0.08 | 1.94 (1.13–3.33) | 0.02 | |
| 392 | GG | 1.00 (reference) | 1.00 (reference) | ||
| GA | 1.24 (0.84–1.81) | 0.28 | 1.64 (1.09–2.47) | 0.02 | |
| AA | 1.55 (0.94–2.55) | 0.08 | 1.94 (1.13–3.33) | 0.02 | |
| 622 | TT | 1.00 (reference) | 1.00 (reference) | ||
| TC | 1.04 (0.73–1.47) | 0.84 | 1.34 (0.91–1.96) | 0.14 | |
| CC | 0.89 (0.42–1.86) | 0.75 | 1.34 (0.57–3.16) | 0.51 | |
| 756 | GG | 1.00 (reference) | 1.00 (reference) | ||
| GA | 1.36 (0.94–1.97) | 0.11 | 1.32 (0.88–1.99) | 0.18 | |
| AA | 2.12 (0.35–12.81) | 0.41 | 0.49 (0.12–1.98) | 0.32 |
*
P‐value was calculated by logistic regression analysis. P 1, HCC patients versus control; P 2, HCC patients versus hepatitis B virus (HBV) carrier.
OR and 95% CI of homozygote and heterozygote carriers of the at‐risk allele were determined with reference to homozygotes of the wild‐type allele. OR1, HCC patients versus control; OR2, HCC patients versus HBV carrier.